Is subcutaneous enoxaparin (Lovenox) appropriate for acute coronary syndrome?

Subcutaneous Enoxaparin for Acute Coronary Syndrome

Yes, subcutaneous enoxaparin is appropriate and FDA-approved for acute coronary syndrome, with proven efficacy in both unstable angina/non-ST-elevation MI and ST-elevation MI when used at the correct dose and duration. 1

FDA-Approved Indications and Dosing

Enoxaparin is specifically indicated for prophylaxis of ischemic complications in unstable angina and non-Q-wave MI when administered with aspirin, and for treatment of acute STEMI with or without subsequent PCI. 1

Standard Dosing Regimens

For unstable angina/NSTEMI:

• 1 mg/kg subcutaneously every 12 hours in conjunction with aspirin (100-325 mg daily) 1
• Continue for minimum 2 days until clinical stabilization 1
• Usual duration is 2-8 days; up to 12.5 days has been studied 1

For STEMI (age <75 years):

• 30 mg IV bolus followed immediately by 1 mg/kg subcutaneous 1
• Then 1 mg/kg subcutaneous every 12 hours 1
• Continue until hospital discharge or maximum 8 days 1

For STEMI (age ≥75 years):

• No IV bolus 1
• 0.75 mg/kg subcutaneous every 12 hours (reduced dose due to bleeding risk) 1

Critical Renal Dosing Adjustments

For creatinine clearance <30 mL/min:

• Reduce to 1 mg/kg subcutaneous once daily (not twice daily) 2, 1
• This adjustment is mandatory—failure to dose-adjust increases major bleeding risk 3.9-fold (OR 3.88; 95% CI 1.78-8.45) 3
• If renal function deteriorates further or dialysis is required, switch to unfractionated heparin with aPTT monitoring 2

Evidence of Efficacy

The ExTRACT-TIMI 25 trial demonstrated that enoxaparin significantly reduced the 30-day composite endpoint of death or MI compared to unfractionated heparin in STEMI patients (9.9% vs 12.0%, 17% relative risk reduction, P=0.000003). 1 This benefit was maintained at 12 months and was consistent across all major subgroups including age, gender, and fibrinolytic agent used. 1

For NSTEMI/unstable angina, pooled data from the ESSENCE and TIMI 11B trials showed enoxaparin was more effective than UFH in reducing death, MI, or urgent revascularization. 4, 5

Use with Early Invasive Strategy and PCI

Timing considerations for PCI:

• If last subcutaneous dose was <8 hours before balloon inflation: no additional dosing needed 1
• If last subcutaneous dose was >8 hours before balloon inflation: give 0.3 mg/kg IV bolus 1

Enoxaparin can be safely continued through PCI without switching to UFH, providing adequate anticoagulation with anti-Xa levels of approximately 0.9 U/mL. 6, 7 Studies show comparable or better outcomes versus UFH when combined with glycoprotein IIb/IIIa inhibitors during early invasive approaches. 6, 7

Special Circumstance: Patients on Warfarin

If patient is on therapeutic warfarin (INR ≈2.5):

• Do not add enoxaparin—this creates dual anticoagulation with markedly increased bleeding risk and limited reversibility (ACC Class IIb recommendation) 8
• Use unfractionated heparin instead, which can be titrated with aPTT and rapidly reversed with protamine 8
• If warfarin is held and INR falls below 2.0, enoxaparin 1 mg/kg twice daily may then be considered 8

Bleeding Risk and Safety

Major bleeding rates are modestly higher with enoxaparin versus UFH (2.1% vs 1.4% at 30 days in STEMI), but this is offset by superior efficacy, resulting in net clinical benefit. 1, 9

Critical dosing errors to avoid:

• In the CRUSADE registry, 18.7% of patients received excess doses (>10 mg above recommended), which significantly increased major bleeding (OR 1.43) and death (OR 1.35) 10
• Excess dosing occurred most commonly in elderly, smaller, and female patients 10
• Always calculate actual body weight-based dosing and apply age/renal adjustments 10

Advantages Over Unfractionated Heparin

Enoxaparin offers several practical advantages: 11, 5

• Greater bioavailability and more predictable anticoagulation
• Fixed dosing without need for aPTT monitoring
• Lower incidence of heparin-induced thrombocytopenia
• Subcutaneous administration (no IV infusion required)

Duration of Therapy

Continue enoxaparin until one of the following occurs: 2, 1

• Successful PCI is performed
• Clinical stabilization is achieved
• Hospital discharge (whichever comes first)
• Maximum duration: 8 days for STEMI 1, 12.5 days for NSTEMI 1

When transitioning to oral anticoagulation (warfarin), overlap enoxaparin for minimum 5 days and until INR is 2.0-3.0. 1